Latest News and Press Releases

EXTON, PA, April 14, 2025 (GLOBE NEWSWIRE) -- Johnson & Johnson’s recent announcement of positive Phase 3 data for its oral IL-23 receptor antagonist, icotrokinra (JNJ-2113), has sparked notable...

EXTON, PA, April 10, 2025 (GLOBE NEWSWIRE) -- As treatment approaches for cutaneous lupus erythematosus (CLE) continue to evolve, new data from Spherix Global Insights shed light on how specialists...

EXTON, PA, April 10, 2025 (GLOBE NEWSWIRE) -- In 2025, the Inflation Reduction Act (IRA) introduced significant Medicare reforms designed to reduce financial burdens for patients, including a new...

EXTON, PA, April 08, 2025 (GLOBE NEWSWIRE) -- Spherix Global Insights has released the first edition of its new Patient Dynamix™: IgA Nephropathy (US) series, delivering a comprehensive look at the...

EXTON, PA, March 28, 2025 (GLOBE NEWSWIRE) -- The treatment landscape for Crohn’s disease continues to evolve with the recent FDA approval of Johnson and Johnson Innovative Medicine’s Tremfya...

EXTON, PA, March 27, 2025 (GLOBE NEWSWIRE) -- In late 2024, Bristol Myers Squibb announced positive topline results from its pivotal Phase 3 trials, POETYK PsA-1 and PsA-2, evaluating Sotyktu...

EXTON, PA, March 27, 2025 (GLOBE NEWSWIRE) -- Tucker Hurtado, Vice President of Product Planning at Spherix Global Insights, has been named a 2025 Luminary by the Healthcare Businesswomen’s...

EXTON, PA, March 26, 2025 (GLOBE NEWSWIRE) -- Nearly all nephrologists agree that early and aggressive intervention is essential for improving outcomes in IgA nephropathy (IgAN). However, findings...

EXTON, PA, March 26, 2025 (GLOBE NEWSWIRE) -- The hemophilia treatment landscape is rapidly evolving, with newly launched therapies and gene therapies joining factor replacement therapies,...

EXTON, PA, March 18, 2025 (GLOBE NEWSWIRE) -- Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare and debilitating blood disorder that affects approximately 8,000 to 10,000 people in North America...